TA
TELO icon

Tactive Advisors’s Telomir Pharmaceuticals TELO Stock Holding History

Tactive Advisors’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,000
Closed -$12.5K – 271
2025
Q2 		$12.5K Buy
+10,000
New +$23.1K ﹤0.01% 228

Other funds holding TELO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $798M AUM 14.62% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Tactive Advisors's TELO Position: Q3 2025 in Review

Tactive Advisors sold out of Telomir Pharmaceuticals (TELO) in Q3 2025, closing a stake of 10,000 shares — an estimated $12.5K sold.

Tactive Advisors first reported a position in TELO in Q2 2025 and held it in 1 quarter. The position peaked at $12.5K in Q2 2025. 32 funds tracked by Wall St. Rank hold TELO as of Q3 2025.

  • Tactive Advisors reported no remaining Telomir Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Tactive Advisors sold 10,000 Telomir Pharmaceuticals shares in Q3 2025, an estimated $12.5K.
  • Tactive Advisors first reported a position in Telomir Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Tactive Advisors's Telomir Pharmaceuticals position peaked at $12.5K in Q2 2025.
  • 32 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q3 2025.

Based on Tactive Advisors's 13F filing for Q3 2025, filed 14 Oct 2025.